|
Finch Therapeutics Group Inc (NASDAQ: FNCH) |
|
Finch Therapeutics Group Inc
FNCH's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Finch Therapeutics Group Inc 's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
growth of revenues by 12.11 %
Finch Therapeutics Group Inc net loss decreased from $-7 millions, to $-5 millions in II. Quarter 2024,
• More on FNCH's Growth
|
|
Finch Therapeutics Group Inc realized a net loss in trailing twelve months.
Finch Therapeutics Group Inc realized cash reduction of $ -11.2 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.52.
• More on FNCH's Valuation
|
|
|
|
|
Finch Therapeutics Group Inc realized net loss in trailing twelve months.
Finch Therapeutics Group Inc realized cash outflow of $ -11.2per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.52.
Finch Therapeutics Group Inc Price to Book Ratio is at 1.59 lower than Industry Avg. of 1389.44. and higher than S&P 500 Avg. of 0.01
• More on FNCH's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com